Apricus Biosciences, Inc.

Apricus Bio (Nasdaq:APRI) is a pharmaceutical company that has an approved product, Vitaros®, for the treatment of ED. Vitaros® is approved in Europe and Canada and will be commercialized by Apricus’ marketing partners, which include Abbott Laboratories Limited, Takeda Pharmaceuticals International GmbH, Hexal AG (Sandoz), and Bracco SpA. Femprox®, the Company’s product candidate for the treatment of FSAID, has successfully completed a nearly 400-subject proof-of-concept study. Our vision is to be a leader in the development and commercialization of innovative products that improve sexual health. Apricus Biosciences is headquartered in San Diego, CA and is publicly traded on the Nasdaq Capital Market under the ticker symbol APRI.